Early Promise for New Agent in Congenital Hyperinsulinism in Kids

Exendin-(9-39) may offer some children born with this rare disease, which results in excessively low blood glucose, an alternative to near-total pancreatectomy.

Related Keywords

University Of Pennsylvania ,Pennsylvania ,United States ,Philadelphia ,Poxel Pharma ,Darko Stefanovski ,Zealand Pharma ,National Center ,National Institutes Of Health ,Drug Administration ,Division Of Endocrinology ,Research Resources ,European Medicines Agency ,Katherine Goldsmith Foundation ,Crinetics Pharmaceuticals ,Diabetes Care ,Medscape Medical ,Congenital Hyperinsulinism Center ,Very High Unmet ,Most Severe Hyperinsulinism Types ,Eiger Biopharmaceuticals ,Prevented Hypoglycemia ,National Institutes ,Katherine Goldsmith ,Hanmi Pharmaceutical ,Heptares Therapeutics ,Tiburio Therapeutics ,Hypoglycemia ,Persistent Hyperinsulinemic Hypoglycemia Of Infancy ,Congenital Hyperinsulinism ,Ongenital Hyperinsulinemic Hypoglycemia ,Diabetes Mellitus ,Hyperinsulinemia ,Endocrinology ,Ndocrine System ,Children ,Child ,Childhood ,Ediatrics ,Kids ,Reactive Hypoglycemia ,Pancreatectomy ,Birth ,Developmental Delay ,Us Food And Drug Administration ,Nited States Food And Drug Administration ,Fda ,Glp 1 R ,